Fusion Antibodies (LON:FAB) Issues Quarterly Earnings Results

Fusion Antibodies (LON:FAB) issued its quarterly earnings data on Monday. The company reported GBX (1.20) EPS for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative return on equity of 210.32% and a negative net margin of 91.92%.

Fusion Antibodies Price Performance

Shares of FAB stock opened at GBX 11.01 on Wednesday. Fusion Antibodies has a 1 year low of GBX 9 and a 1 year high of GBX 21. The firm’s 50 day moving average is GBX 10.82 and its 200-day moving average is GBX 12.14. The firm has a market capitalization of £13.78 million, a price-to-earnings ratio of -7.34 and a beta of 1.24. The company has a current ratio of 1.80, a quick ratio of 2.36 and a debt-to-equity ratio of 92.42.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.